Venture Investing In Biotech Still Strong, Says E&Y Report
This article was originally published in The Pink Sheet Daily
Executive Summary
The 27th annual Beyond Borders report shows continued constraints to funding for biotechs, as they cut R&D and deal with a changing development landscape, but VC funding remains resilient.
You may also be interested in...
As Some New Listings Thrive, IPO Pipeline Burgeons
Encouraging results from some early 2013 offerings have led to four new filings in April. If the pattern holds, this year could be a better year for new listings than 2012.
Aastrom Stands Behind Its Decision To Shift Gears In Late Stages
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.
Third Rock Continues To Attract Investors, Closes $516M Fund
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: